Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Index
-
Market Cap
36.00M
Enterprise Value
10.28M
Income
-15.99M
Sales
0.00M
Book/sh
1.63
Cash/sh
1.35
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
11
IPO
Sep 05, 2002
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
1.15
P/C
1.39
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
14.52
Current Ratio
14.52
Debt/Eq
0.00
LT Debt/Eq
0.00
Option/Short
No / Yes
EPS (ttm)
-0.90
EPS next Y
-0.32
EPS next Q
-
EPS this Y
-229.19%
EPS next Y
-30.76%
EPS next 5Y
-
EPS past 3/5Y
80.11% 66.10%
Sales past 3/5Y
- -
EPS Y/Y TTM
96.65%
Sales Y/Y TTM
-
EPS Q/Q
-155.28%
Sales Q/Q
-
Insider Own
4.67%
Insider Trans
5.64%
Inst Own
1.97%
Inst Trans
50.60%
ROA
-51.53%
ROE
-55.71%
ROIC
-53.83%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-14.36%
SMA50
-35.74%
SMA200
-51.81%
Trades
Shs Outstand
19.10M
Shs Float
18.20M
52W High
5.89 -68.01%
52W Low
1.70 10.88%
Volatility
11.93% 12.75%
ATR (14)
0.29
RSI (14)
30.33
Beta
0.36
Rel Volume
0.75
Avg Volume
87.72K
Volume
51,444
Perf Week
-18.75%
Perf Month
-22.43%
Perf Quarter
-60.73%
Perf Half Y
-55.85%
Perf YTD
-38.80%
Perf Year
-50.32%
Perf 3Y
-20.80%
Perf 5Y
-83.02%
Perf 10Y
-93.04%
Prev Close
1.96
Price
1.88
Change %
-3.83%
Consensus
Strong Buy
Avg. Price Target
$17.21
Implied Upside
+813.0%
Analysts4incl. previous ratings
Rating Distribution3 Buy · 1 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Aug 11, 2026Initiated
CCraig Hallum
Buy$12+536.6%
Jun 16, 2026Resumed
LLadenburg Thalmann
Buy$10+430.5%
Feb 03, 2025Downgrade
TThe Benchmark Company
Speculative Buy → Hold
Dec 12, 2024Initiated
MMaxim Group
Buy$8+324.4%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Marks Peter AshleyDirectorAug 31 '26Buy0.5047,62023,810191,340Sep 08 07:01 PM
Alterity Therapeutics Ltd. engages in the business of research and development of therapeutic drugs designed to treat neurodegenerative diseases, focusing on Parkinsonian and other movement disorders. Its lead candidate, ATH434, is an oral small molecule drug designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.
CEODr. David A. Stamler M.D.
B.Sc.Ms. Abby Macnish Niven B.Com.
Chief Scientific Advisor and Member of Research & Development Advisory BoardDr. Rudolph Emile Tanzi Ph.D.
Chief Medical AdvisorDr. Steven D. Targum M.D.
Head of ResearchDr. Robert Cherny